Destiny Pharma PLC (AIM:DEST, OTC:DTTYF) CEO, Neil Clark presents at the Proactive One2One Investor Forum.
Destiny is a clinical-stage biotechnology company focused on the development of novel medicines that can prevent life-threatening infections.
Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence, which is the leading cause of hospital-acquired infection in the US.
Destiny is also advancing XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA.